Skip to Content

Lomitapide Disease Interactions

There are 5 disease interactions with lomitapide:

Major

Lomitapide (applies to lomitapide) liver impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The use of lomitapide is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C), and patients with active liver disease, including unexplained elevations of serum transaminases. Lomitapide increases hepatic fat, with or without concomitant increases in transaminases. Hepatic steatosis associated with the use of lomitapide may be a risk factor for progressive liver disease including steatohepatitis and cirrhosis. Patients with mild liver impairment should not exceed 40 mg daily as exposure can increase up to 50% compared with healthy volunteers.

Moderate

Lomitapide (applies to lomitapide) alcohol

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Alcoholism

Alcohol may increase the levels of hepatic fat and induce or exacerbate liver injury. It is recommended that patients taking lomitapide should not consume more than one alcoholic drink per day.

Moderate

Lomitapide (applies to lomitapide) galactosemia

Moderate Potential Hazard, Moderate plausibility.

Patients with rare, hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should avoid lomitapide as this may result in diarrhea or malabsorption.

Moderate

Lomitapide (applies to lomitapide) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Patients with end-stage renal disease receiving dialysis should not exceed 40 mg daily of lomitapide, as exposure can increase up to 50% compared with healthy volunteers. Effects of mild, moderate, and severe renal impairment, including end-stage renal disease not yet receiving dialysis, on lomitapide exposure have not been studied. Caution is advised.

Moderate

Lomitapide (applies to lomitapide) vitamin deficiency

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Malabsorption Syndrome

Lomitapide may reduce the absorption of fat soluble nutrients. Patients on clinical trials were provided with daily dietary supplements of vitamin E, linoleic acid, alpha- linoleic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). Patients with chronic bowel or pancreatic diseases that predispose to malabsorption may be at increased risk for deficiencies in these nutrients with the use of lomitapide. Patients receiving treatment should take daily vitamin supplements.

Lomitapide drug interactions

There are 453 drug interactions with lomitapide

Lomitapide alcohol/food interactions

There is 1 alcohol/food interaction with lomitapide

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.